EupholCAS# 514-47-6 |
- Tirucallol
Catalog No.:BCN7787
CAS No.:514-46-5
- Lanosterol
Catalog No.:BCN3332
CAS No.:79-63-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 514-47-6 | SDF | Download SDF |
PubChem ID | 441678 | Appearance | Powder |
Formula | C30H50O | M.Wt | 426.71 |
Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (3S,5R,10S,13S,14S,17S)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol | ||
SMILES | CC(CCC=C(C)C)C1CCC2(C1(CCC3=C2CCC4C3(CCC(C4(C)C)O)C)C)C | ||
Standard InChIKey | CAHGCLMLTWQZNJ-WZLOIPHISA-N | ||
Standard InChI | InChI=1S/C30H50O/c1-20(2)10-9-11-21(3)22-14-18-30(8)24-12-13-25-27(4,5)26(31)16-17-28(25,6)23(24)15-19-29(22,30)7/h10,21-22,25-26,31H,9,11-19H2,1-8H3/t21-,22+,25+,26+,28-,29+,30-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Euphol, a novel cannabinoid agonist, prevents inflammatory and neuropathic persistent pain in rodents. 2. Euphol arrests breast cancer cells at the G1 phase through the modulation of cyclin D1, p21 and p27 expression. 3. Euphol has anti-inflammatory action, it can prevent experimental autoimmune encephalomyelitis in mice. |
Targets | NOS | TNF-α | COX | CDK | p21 | IL Receptor |
Euphol Dilution Calculator
Euphol Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3435 mL | 11.7176 mL | 23.4351 mL | 46.8702 mL | 58.5878 mL |
5 mM | 0.4687 mL | 2.3435 mL | 4.687 mL | 9.374 mL | 11.7176 mL |
10 mM | 0.2344 mL | 1.1718 mL | 2.3435 mL | 4.687 mL | 5.8588 mL |
50 mM | 0.0469 mL | 0.2344 mL | 0.4687 mL | 0.9374 mL | 1.1718 mL |
100 mM | 0.0234 mL | 0.1172 mL | 0.2344 mL | 0.4687 mL | 0.5859 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Tirucallol
Catalog No.:BCN7787
CAS No.:514-46-5
- Parkeol
Catalog No.:BCN3728
CAS No.:514-45-4
- Periplogenin
Catalog No.:BCN2656
CAS No.:514-39-6
- Abietic acid
Catalog No.:BCN2728
CAS No.:514-10-3
- Taraxerone
Catalog No.:BCN5636
CAS No.:514-07-8
- 2-(2-Aminoethyl)-1-methylpyrrolidine
Catalog No.:BCC8477
CAS No.:51387-90-7
- Boc-Methioninol
Catalog No.:BCC2720
CAS No.:51372-93-1
- Tris DBA
Catalog No.:BCC7685
CAS No.:51364-51-3
- delta-Amyrin acetate
Catalog No.:BCN5635
CAS No.:51361-60-5
- Budesonide
Catalog No.:BCC4767
CAS No.:51333-22-3
- Soyasaponin Bb
Catalog No.:BCN2598
CAS No.:51330-27-9
- Aloe-emodin-glucoside
Catalog No.:BCC8130
CAS No.:29010-56-8
- Ferruginol
Catalog No.:BCN3155
CAS No.:514-62-5
- Biperiden
Catalog No.:BCC4274
CAS No.:514-65-8
- Canthaxanthin
Catalog No.:BCC8139
CAS No.:514-78-3
- Alrestatin
Catalog No.:BCC6663
CAS No.:51411-04-2
- Chikusetsusaponin IVa
Catalog No.:BCN3432
CAS No.:51415-02-2
- Odonicin
Catalog No.:BCN5637
CAS No.:51419-51-3
- 3-Methyladenine
Catalog No.:BCC3714
CAS No.:5142-23-4
- COG 133
Catalog No.:BCC1047
CAS No.:514200-66-9
- Cyclo(Tyr-Phe)
Catalog No.:BCN2423
CAS No.:5147-17-1
- Deoxynivalenol
Catalog No.:BCC7832
CAS No.:51481-10-8
- Cimetidine
Catalog No.:BCC4527
CAS No.:51481-61-9
- PMX 205
Catalog No.:BCC8039
CAS No.:514814-49-4
Euphol arrests breast cancer cells at the G1 phase through the modulation of cyclin D1, p21 and p27 expression.[Pubmed:23969579]
Mol Med Rep. 2013 Oct;8(4):1279-85.
Euphorbia tirucalli is a longestablished treatment for a wide variety of cancers. However, the mechanism of its anticancer effect is yet to be elucidated. In the present study, we examined the anticancer effect of Euphol, a tetracyclic triterpene alcohol isolated from the sap of Euphorbia tirucalli, in T47D human breast cancer cells. Following the treatment of cells with different doses of Euphol for 24, 48 and 72 h, the cell proliferation, cell cycle, and mRNA and protein levels of cell cycle regulatory molecules were analyzed, respectively. Treatment of the cells with Euphol resulted in decreased cell viability, which was accompanied by an accumulation of cells in the G1 phase. Further studies demonstrated that Euphol treatment downregulated cyclin D1 expression and the hypophosphorylation of Rb. Furthermore, this effect was correlated with the downregulation of cyclindependent kinase 2 (CDK2) expression and the upregulation of the CDK inhibitors p21 and p27. Reduced expression levels of cyclin A and B1 were also observed, corresponding to the decreased distribution of cells in the S and G2/M phases, respectively. These findings indicated that Euphol is an active agent in Euphorbia tirucalli that exerts anticancer activity by arresting the cell cycle of cancer cells.
Euphol, a tetracyclic triterpene produces antinociceptive effects in inflammatory and neuropathic pain: the involvement of cannabinoid system.[Pubmed:22613837]
Neuropharmacology. 2012 Sep;63(4):593-605.
Persistent pains associated with inflammatory and neuropathic states are prevalent and debilitating diseases, which still remain without a safe and adequate treatment. Euphol, an alcohol tetracyclic triterpene, has a wide range of pharmacological properties and is considered to have anti-inflammatory action. Here, we assessed the effects and the underlying mechanisms of action of Euphol in preventing inflammatory and neuropathic pain. Oral treatment with Euphol (30 and 100 mg/kg) reduced carrageenan-induced mechanical hyperalgesia. Likewise, Euphol given through the spinal and intracerebroventricular routes prevented mechanical hyperalgesia induced by carrageenan. Euphol consistently blocked the mechanical hyperalgesia induced by complete Freund's adjuvant, keratinocyte-derived chemokine, interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha associated with the suppression of myeloperoxidase activity in the mouse paw. Oral treatment with Euphol was also effective in preventing the mechanical nociceptive response induced by ligation of the sciatic nerve and also significantly reduced the levels and mRNA of cytokines/chemokines in both paw and spinal cord tissues following i.pl. injection of complete Freund's adjuvant. In addition, the pre-treatment with either CB(1)R or CB(2)R antagonists, as well as the knockdown gene of the CB(1)R and CB(2)R, significantly reversed the antinociceptive effect of Euphol. Interestingly, even in higher doses, Euphol did not cause any relevant action in the central nervous system. Considering that few drugs are currently available for the treatment of chronic pain states, the present results provided evidence that Euphol constitutes a promising molecule for the management of inflammatory and neuropathic pain states.
Euphol prevents experimental autoimmune encephalomyelitis in mice: evidence for the underlying mechanisms.[Pubmed:22155310]
Biochem Pharmacol. 2012 Feb 15;83(4):531-42.
Multiple sclerosis (MS) is a severe chronic T cell-mediated autoimmune inflammatory disease of the central nervous system (CNS), the existing therapy of which is only partially effective and is associated with undesirable side effects. Euphol, an alcohol tetracyclic triterpene, has a wide range of pharmacological properties and is considered to have anti-inflammatory action. However there are no reports about the effects and mechanisms of Euphol in experimental autoimmune encephalomyelitis (EAE), an established model of MS. Here we report the effects and the underlying mechanisms of action of Euphol in EAE. Euphol (1-10mg/kg) was administered orally at different time-points of EAE. Immunological and inflammatory responses were evaluated by real-time PCR, Western blot and flow cytometry assays. We provide evidence that Euphol significantly attenuates neurological signs of EAE. These beneficial effects of Euphol seem to be associated with the down-regulation of mRNA and protein expression of some pro-inflammatory mediators such as TNF-alpha, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in the CNS. Furthermore, in vitro, Euphol consistently inhibited the T cell-mediated immune response including the production of T(H)1 and T(H)17 cytokines in spleen cells of untreated EAE animals. Likewise, oral Euphol treatment inhibited the infiltration of T(H)17 myelin-specific cells into the CNS through the adhesion molecule, lymphocyte function-associated antigen 1 (LFA-1). Our findings reveal that oral administration of Euphol consistently reduces and limits the severity and development of EAE. Therefore, Euphol might represent a potential molecule of interest for the treatment of MS and other T(H)17 cell-mediated inflammatory diseases.